Healthcare | June 15, 2024
Fischer Medical Ventures and The Therapy Platform partner for mental healthcare
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
EDQM has also issued a Certificate of Suitability for Allopurino
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Subscribe To Our Newsletter & Stay Updated
